May 10, 2006
NEW YORK, Wednesday, May 10 - John McGoldrick, J.D., former Executive Vice President of Bristol-Myers Squibb (BMS); and Stephen Udem, M.D., Ph.D., who was the Vice President, Exploratory Vaccine Discovery Research at Wyeth Vaccines Research are joining the International AIDS Vaccine Initiative (IAVI) - a leading international AIDS vaccine product development partnership.
Mr. McGoldrick joins IAVI as the Senior Vice President, External Strategy Development. In this role, Mr. McGoldrick will provide strategic leadership in developing and implementing plans for the organization’s fundraising efforts and external relationships in both the public and private sectors. Dr. Udem’s title will be Senior Vice President of Vaccine Development and Chief Scientific Officer at IAVI. He will manage IAVI’s vaccine development programs and also provide strategic leadership across all scientific programs.
“Part of IAVI’s strategy for addressing today’s challenges in HIV/AIDS is recruiting to this cause the talents of leading and seasoned professionals who can apply their skills and passion towards our mission,” said Seth Berkley, M.D., President and CEO of IAVI. “Mr. McGoldrick and Dr. Udem will add significantly to IAVI’s team of outstanding professionals and will bring to our efforts extensive and unique experiences as former senior executives at leading pharmaceutical companies,” continued Dr. Berkley.
Mr. McGoldrick brings extensive experience to his new position. While at BMS, he reported to the CEO and had overall responsibility for Law, Global Corporate Policy, Government Affairs, and Philanthropy. He also served as a Director of the BMS Foundation, and as President of the Medical Devices Group.
Mr. McGoldrick had been responsible for the $150 million “Secure The Future” program which continues at BMS to develop models for treatment of HIV/AIDS in nine African countries. At BMS, he had been instrumental in other initiatives against HIV, including reducing prices to no-profit levels, non-enforcement of patents in Africa, technology transfer to generics, and recently, the donation of a promising topical microbicide. He had been a principal and served as Chair of the Accelerating Access Initiative (AAI), the international collaboration of drug companies and five U.N.-led international agencies to increase access to antiretroviral therapy. Previously he was a senior partner at the firm of McCarter & English. He received undergraduate and law degrees from Harvard.
Dr. Udem is an internationally recognized virologist and vaccinologist, considered especially expert in the fields of negative-strand RNA viruses and the design and development of viral vectors. While his focus at Wyeth was Vaccine Discovery Research for which he led a department of 150 researchers, his activities and responsibilities were far broader and included vaccine candidate development, regulatory submission, intellectual property assessment, and occasionally product licensure. Prior to joining industry, Dr. Udem held senior academic positions at the Albert Einstein College of Medicine and the New Jersey Medical School. His scientific efforts in academia as well as in industry have been supported by extramural grants and contracts, and his teaching talent has been repeatedly recognized in awards and honors. In addition, Dr. Udem’s contributions have been extensively published in the scientific literature and many of his creative technology inventions have been patented. He received his undergraduate degree from City College of New York and his Ph.D. and M.D. from Albert Einstein College of Medicine.
Perhaps the most relevant to IAVI is Dr. Udem’s extensive clinical experience, particularly his tenure as New Jersey Medical School’s Director of Infectious Diseases, during which he designed, built and introduced a state-of-the-art in-patient AIDS ward and out-patient services. It is this very confluence of clinical and scientific experience that will allow him to effectively provide strategic leadership to all of IAVI’s scientific and clinical programs. Dr. Udem will work in close partnership with Wayne Koff, Ph.D., Senior Vice President of Vaccine Research, to identify, design, and develop the next generation of AIDS vaccine candidates through collaborations with industry, academia and governments.
Currently IAVI has an active research and development program worldwide that includes the initiation and oversight of multiple AIDS vaccine clinical trials in Eastern and Southern Africa, Europe, India, and the United States. IAVI has more then 40 research and development collaborations that include industry partners such as: Crucell, GSK Biologicals, Targeted Genetics, and Therion.
The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. Founded in 1996 and operational in 23 countries, IAVI and its network of collaborators research and develop vaccine candidates. IAVI's financial and in-kind supporters include the Alfred P. Sloan Foundation, the Bill & Melinda Gates Foundation, The New York Community Trust, The Rockefeller Foundation, The Starr Foundation; the Governments of the Basque Country, Canada, Denmark, European Union, Ireland, The Netherlands, Norway, Sweden, United Kingdom, and United States; multilateral organizations such as The World Bank; corporate donors including BD (Becton, Dickinson & Co.), Continental Airlines, DHL and Pfizer; leading AIDS charities such as Broadway Cares/Equity Fights AIDS, Crusaid, Deutsche AIDS-Stiftung, and Until There's A Cure Foundation; other private donors such as the Haas Charitable Trusts; and many generous individuals from around the world.